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Summary
Background—Several risk factors for inhibitors have recently been described for hemophilia A. 
It has been assumed that similar risk factors are also relevant for hemophilia B, but there is limited 
data to confirm this notion.
Objectives—To determine the prevalence of and risk factors associated with inhibitors in 
hemophilia B
Methods—The database of the Universal Data Collection (UDC) project of the Centers for 
Disease Control for the years 1998 – 2011 was queried to determine the prevalence of inhibitors in 
hemophilia B subjects. In addition, disease severity, race/ethnicity, age, factor exposure, and 
prophylaxis usage were evaluated to determine their impact on inhibitor prevalence.
Results—Of the 3800 male subjects with hemophilia B enrolled in the UDC database, 75 (2%) 
were determined to have an inhibitor at some point during the study period. Severe disease (OR 
13.1, 95% CI 6.2-27.7), black race (OR 2.2, 95% CI 1.2-4.1), and age less than 11 (OR 2.5, 95% 
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CI 1.5-4.0) were found to be significantly associated with having an inhibitor. There was 
insufficient data to determine if type of factor used and prophylaxis were associated with 
inhibitors.
Conclusions—Inhibitors in hemophilia B are much less prevalent than hemophilia A, especially 
in patients with mild disease. Similar factors associated with inhibitors in hemophilia A also seem 
to be present for hemophilia B. The information collected by this large surveillance project did not 
permit evaluation of potential risk factors related to treatment approaches and exposures, and 
additional studies will be required.
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Introduction
The development of an inhibitor is one of the most devastating complications of hemophilia. 
In recent years, several risk factors for inhibitor formation in patients with hemophilia have 
been proposed. These include severity of disease, type of mutation, race, intensity of 
coagulation factor use at first exposure, type of coagulation product used, prophylaxis, 
surgery, and other immune related genetic polymorphisms [1]. Data supporting the 
importance of these risk factors for inhibitor development have derived primarily from the 
study of hemophilia A. It is assumed that similar risk factors for inhibitor development are 
present in patients with hemophilia B. However, this assumption may not be valid, 
especially considering that the clinical behavior of factor IX inhibitors differs from factor 
VIII inhibitors in important ways. The most significant of these are that factor IX inhibitors 
may be associated with allergic and hypersensitivity reactions; attempts to eliminate factor 
IX inhibitors with immune tolerance induction (ITI) regimens can lead to the development 
of nephrotic syndrome; and standard ITI succeeds in a minority of attempts [2-4]. Risk 
factors for inhibitor development in patients with hemophilia B have never been evaluated in 
an independent, systematic way. Likewise, the prevalence of inhibitors in patients with 
hemophilia B has generally been estimated using data from small, single institution studies, 
or from clinical trials of new factor IX products [5-7]. A large survey of North American 
Hemophilia Treatment Centers (HTC) found a prevalence of inhibitors in hemophilia B 
patients of 1.5%. However, nearly half the HTCs failed to respond to the survey, and the 
results of this survey may have been subject to bias [8].
To address these issues, we performed a descriptive analysis of a large database of bleeding 
disorders patients enrolled in the Universal Data Collection (UDC) study sponsored by the 
Centers for Disease Control (CDC) in Atlanta, U.S.A. The focus of this review was to 
determine the prevalence of and risk factors associated with inhibitors in hemophilia B 
subjects enrolled in the UDC database.
Materials and Methods
The UDC was established by the United States CDC as a national public health surveillance 
system to monitor treatment and outcomes of people with bleeding disorders.[9] Patients 
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with hemophilia A and B, Von Willebrand Disease, and rare coagulation factor deficiencies 
who receive treatment at one of the 130 federally funded Hemophilia Treatment Center 
(HTC) in the United States are eligible to participate in the UDC. The 130 federally funded 
HTCs comprise the Hemophilia Treatment Center Network (HTCN), and investigators from 
each site contributed data to this study.
Data were collected by HTC staff from 1998 - 2011 using standardized data collection 
forms. At study enrollment data were collected regarding age, sex, race/ethnicity, bleeding 
disorder diagnosis, severity of factor deficiency, age and site of first bleed, family history of 
a bleeding disorder, history of intracranial hemorrhage, and genotype if available (not 
required for enrollment). For children less than 2 years of age at study enrollment, details 
regarding the birth history were also collected. For all age groups, data regarding allergic or 
hypersensitivity reactions, a prior history of an inhibitor, prior factor usage, treatment type 
(episodic/prophylactic infusions, or immune tolerance induction) prior to enrollment, and 
intensity of exposure at first usage were not collected. Race/Ethnicity was based on self-
report and categorized as White (non-Hispanic), White (Hispanic), Black (non-Hispanic), 
Black (Hispanic), Asian/Pacific Islander, Native American, and other.
At subsequent UDC visits data regarding factor product(s) received, frequency of bleeds, 
treatment type (episodic, prophylaxis, ITI), joint range of motion, HIV and hepatitis C risk 
management and status, and highest inhibitor titer measured in Bethesda Units (BU) ml−1 
since the last visit were collected.
The Institutional Review Boards of each participating HTC and the CDC approved the UDC 
and all participants or parents of minor children gave informed consent for data collection 
and transmission.
The database was queried to identify all hemophilia B patients entered into the database 
from May 1998 until September 2011. Of this subset, potential hemophilia B inhibitor cases 
were identified by the presence of any inhibitor titer ≥ 0.5 BU ml−1, or by the report of 
treatment to establish immune tolerance, or by the use of bypassing agents. At each site with 
potential hemophilia B inhibitor subjects, the participating institution (PI) was given the 
highest recorded inhibitor titer in the UDC database for potential inhibitor subjects from 
their center and asked via email to 1) confirm the accuracy of the submitted UDC data; and 
2) to verify whether or not the patient had an inhibitor. Institutions that did not respond to 
the initial emails were sent up to two additional requests to confirm the data.
If the reported titer was incorrect, the PI was asked to provide the correct titer value. If the 
PI verified that the patient had an inhibitor, the PI was asked to classify the inhibitor into 
one of the following categories: 1) high titer inhibitor if the inhibitor titer was ≥5 BU ml−1 
on at least two occasions; 2) low titer if the inhibitor titer was between the upper limit of 
normal for the PI’s lab and 5 BU ml−1 on at least two occasions, lasted > 6 months, and was 
not associated with an anamnestic response; and 3) transient if the inhibitor titer was greater 
than the upper limit of normal for the PI’s lab no matter what the peak titer was, lasted ≤ 6 
months, and has never recurred. If the PI verified that the patient never had an inhibitor, the 
patient was categorized as inhibitor negative for the study. Whenever there were 
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discrepancies between the PI confirmed data and the UDC data, the PI confirmed data were 
used for the analysis.
Inhibitor status for the subjects whose PI did not respond to our inquiries was based solely 
on the submitted UDC data and was categorized as follows: 1) high titer if the inhibitor titer 
was ≥ 5 BU ml−1 at any UDC visit; 2) low titer if the highest recorded inhibitor titer in the 
UDC database was greater than 1 BU ml−1 and <5 BU ml−1; and 3) if the titer was between 
0.5 and 1 BU ml−1 then inhibitor status was positive for a low titer inhibitor if the subject 
ever received bypassing agents or immune tolerance induction (ITI) at any UDC visit; 
otherwise, the status was categorized as negative for an inhibitor.
From the UDC dataset, information on disease severity, age, race/ethnicity, prophylaxis and 
type of coagulation concentrates used for each subject was obtained.
Hemophilia severity was determined according to their factor IX activity: severe if less than 
1%, moderate if between 1% and less than or equal to 5.0 %, and mild if greater than 5.0% 
and less than 40%.[10]
Patients were considered on prophylaxis if they received treatment products to prevent 
bleeding or to prevent re-bleeding. Subjects receiving either intermittent or continuous 
prophylaxis were both considered on prophylaxis for the purposes of this study. Patients 
were considered to have received episodic care if they received treatment products only in 
response to bleeding complications.
ITI was defined by the UDC as successful if the patient could be effectively treated for a 
bleeding episode with a factor dosage appropriate to his/her hemophilia severity and its type, 
otherwise it was unsuccessful. This definition of ITI success was established by the UDC at 
the inception of the UDC study and was determined for this study from the standardized 
annual UDC collection form.
Statistical analysis: Differences in the proportion of patients with inhibitors in each category 
of demographic and clinical characteristics were evaluated for statistical significance using 
chi-square tests. Independent associations between these characteristics and inhibitor 
prevalence were assessed using the prevalence odds ratio resulting from a logistic regression 
model. All analysis used the SAS software (SAS Institute, Cary, NC) and associations were 
considered statistically significant when p-values were ≤ 0.05.
Results
At the time of our database query in September, 2011, 3785 male patients with hemophilia B 
had been enrolled in the UDC database. Of these, 985 (26%) had mild, 1418 (38%) had 
moderate, and 1367 (36%) had severe hemophilia B. In 15 subjects (0.4%) these data were 
missing. There were 203 potential subjects with a reported inhibitor titer ≥0.5 BU ml−1 or 
who were reported to have received immune tolerance therapy or bypass agents at one of 
more UDC visits. Further data were available from the PI for 137 subjects with regard to the 
accuracy of the submitted UDC data and verification of inhibitor status. For the remaining 
66 subjects, inhibitor status was based solely on the data available in the UDC database. 
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Figure 1 provides the details of how both UDC data and PI-supplied data were used to 
classify the inhibitor status of the 203 subjects identified as potential inhibitor cases from the 
initial screening.
When the PI responded to the question regarding the accuracy of the inhibitor titer data in 
the UDC data base, 49 (39%) indicated it was correct, and 78 (61%) indicated that it was 
not. In 10 subjects, the PI did not respond to the question regarding the accuracy of the 
inhibitor titer data, but did respond to other questions during confirmatory correspondence 
so that it could be determined that 9 of these subjects had high titer inhibitors, and one did 
not have an inhibitor. Almost 90% of the time that the PI indicated the inhibitor titer data 
were not correct, the titer in the UDC database was between 0.5 and ≤ 1 BU ml−1, and the PI 
did not consider this subject to have an inhibitor. This was because the titer was below the 
upper limit of normal for the local lab but still ≥ 0.5 BU ml−1, or the PI incorrectly rounded 
any positive titer up to 1 BU ml−1. Of the 87 subjects with inhibitor titers between 0.5 and ≤ 
1 BU ml−1 and no ITI or bypass agent use where the PI responded to our email, 99% were 
categorized as never having an inhibitor based on PI response to our query.
Of the 3785 hemophilia B subjects enrolled into the UDC surveillance project, 75 (2%) had 
an inhibitor at some point during the study period. The majority of subjects (59) had 
evidence of an inhibitor (either elevated inhibitor titer, or receipt of ITI or bypass agent) at 
time of enrollment into the UDC. Among those with an inhibitor, 24 (0.6%) had low titer 
inhibitors, while the remaining 51(1.3%) had high titer inhibitors. Of those with a low titer 
inhibitor, 10 (42%) received treatment with ITI or a bypassing agent during the study period.
Table 1 shows the prevalence of inhibitors across categories of the studied risk factors. Age, 
race/ethnicity, and disease severity were all found to have a statistically significant impact 
on inhibitor prevalence. Children ≤ 10 years of age were more likely than those who were 
older to have a prevalent inhibitor. White non-Hispanic subjects were less likely than 
subjects of any other race or ethnicity to have a prevalent inhibitor. As expected, subjects 
with severe disease were far more likely to have an inhibitor than those with less severe 
disease. Associations between prevalent inhibitors and age and race were not as strong 
among those with low titer inhibitors compared to those whose inhibitor was high titer.
The results of a multivariate analysis are shown in table 2. After adjusting for the effects of 
all the studied factors, subjects under the age of 11 years had 2.5 (95% CI 1.5 – 4.0) times 
the odds of having an inhibitor than subjects who were older. In contrast to the bivariate 
results, only black subjects had higher odds of prevalent inhibitors than white subjects. 
Finally, subjects with severe hemophilia had 13.2 (95% CI 6.2 - 27.7) times the odds of 
having an inhibitor than those with mild or moderate hemophilia B. These associations also 
held true when subjects with high titer inhibitors only were included in the analysis (table 3).
Of the 3785 Hemophilia B patients enrolled in the UDC database, there were a total of 114 
(3%) reported deaths. There was only one (1.3%) reported death among the 75 inhibitor 
subjects.
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Among the 75 patients with an inhibitor, 20 (27%) were reported to have received ITI at any 
UDC visit during the study period. Of these, 8 were reported as failures, 6 were successes, 
and in 6 ITI was ongoing as of the last UDC visit.
Discussion
Our review of this large surveillance database showed that 2% of hemophilia B subjects had 
inhibitors. Because we could not confirm in all cases the presence or absence of an inhibitor 
in subjects prior to enrollment in the UDC, we could not determine the actual proportion of 
inhibitors in this population, but it is unlikely to be much higher than 2% [8]. The majority 
of inhibitors were high titer, with a ratio of almost 2:1 high titer versus low titer. This is 
similar to the ratio found by Katz in his survey of North American Hemophilia Treatment 
Centers [8]. It is interesting to note that almost half of the low titer inhibitor subjects 
received ITI or bypassing agents, suggesting a significant clinical relevance to some low 
titer inhibitor subjects. To our knowledge, this approach has not been reported previously. It 
is possible that low titer subjects were treated with bypassing agents because of or out of 
concern for anaphylactic reactions. Unfortunately, the UDC database did not collect 
information regarding allergic reactions to factor IX products. In addition, the surveillance 
data collected in the UDC does not allow the capture of information regarding whether 
changes to dosing frequency or amount were occasioned by low titer inhibitors. Because this 
would be associated with increased clinical or financial burden, there may have been a 
further clinical relevance to low titer inhibitors.
The reasons for a lower prevalence of inhibitors in hemophilia B compared to hemophilia A 
are unclear. As with hemophilia A we found that underlying disease severity was 
significantly associated with inhibitor prevalence, with an odds ratio of an inhibitor in severe 
hemophilia B of 13.1 (95% CI 6.2 – 27.7) as compared to subjects with mild or moderate 
hemophilia B.
Interestingly, the profile of mutations found in severe hemophilia B differs from that found 
in hemophilia A. Higher proportions of severe hemophilia B patients are a result of missense 
mutations and are cross-reacting material positive (CRM+) [2, 4, 11]. Null mutations in 
hemophilia patients confer a higher risk of inhibitor development. This is true for both 
hemophilia A and hemophilia B [2, 12]. The differences in the ratio of CRM+ to CRM – 
patients in hemophilia A and B may in part explain the lower prevalence of inhibitors in 
hemophilia B. There may also be differences in immunogenicity between the factor VIII and 
factor IX molecule [4]. Our data showing a much lower proportion of prevalent inhibitors in 
mild hemophilia B subjects compared to mild hemophilia A patients supports this notion.
Race/Ethnicity was also related to the presence of an inhibitor. Bivariate analyses suggested 
that non-white race/ethnicity had a higher prevalence of inhibitor formation. However, on 
multivariate analysis, only black race remained associated. This is in contrast to hemophilia 
A, in which this same UDC database revealed that both black race and Hispanic ethnicity 
were related to higher rates of inhibitor formation [13]. However, given the small sample 
size, weak associations cannot be excluded.
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Age was the third factor in this study to show an association with inhibitor status, with age 
less than 11 showing an odds ratio of 2.5 (95% CI 1.5 - 4.0) for prevalent inhibitor. At first 
glance, this is not a surprising result. Since the majority of inhibitors occur within the first 
50 exposure days, one might expect a higher ratio of inhibitors in younger subjects. 
However, even if the incidence of new inhibitor formation is lower in older subjects 
compared to younger subjects, it is not clear why the population prevalence of inhibitors 
reported at annual UDC visits might decrease with advancing age. With hemophilia A, one 
would expect a fall off in inhibitor prevalence with age as 75% of hemophilia A subjects 
with inhibitors are successfully immune tolerized. The success rate for immune tolerance 
induction in hemophilia B subjects is thought to be much lower [2, 3]. We could not 
determine the success rate for ITI in the UDC population because almost one-third of the 
subjects had ongoing ITI therapy at the time of study closure. Alternatively, subjects who 
develop an inhibitor and who subsequently are not exposed to factor IX (for instance, 
subjects whose bleeding episodes are managed exclusively with bypassing agents) may 
experience a diminution in the titer of the factor IX inhibitor to undetectable levels with 
time. Although such an individual would see a rise in inhibitor titer should he be exposed to 
factor IX in the future, he would not have a prevalent inhibitor that would be recorded at the 
time of the UDC visit. Spontaneous loss of high-responder factor VIII inhibitor 
responsiveness has been described in HIV infected individuals with hemophilia A [10, 14]. 
To our knowledge spontaneous loss of high responder factor IX inhibitors has not been 
described in immunodeficient or immunocompetent individuals. Another potential 
explanation is mortality rate. If the mortality rate for inhibitor patients was higher than non-
inhibitor subjects, then one would expect a drop off in prevalent inhibitors with age. In this 
study, the mortality rate of inhibitor subjects was not higher than that of non-inhibitor 
subjects.
Finally, the type(s) of factor to which subjects were exposed could explain the difference in 
prevalent inhibitors between the older population and younger population. Recombinant 
factor IX was introduced to the U.S market over 15 years ago, which may have led to a 
higher exposure to recombinant factor IX at initial exposure in younger subjects as 
compared to older. Several studies of inhibitors arising in hemophilia A suggest a higher risk 
of inhibitor formation in subjects exposed to recombinant factor VIII versus plasma derived 
factor VIII, though definitive studies are lacking [1, 15, 16] We attempted to determine if 
the type of coagulation factor concentrate used was associated with inhibitor formation in 
this study, but could not because we could not adequately determine the type of factor IX 
used prior to inhibitor formation. A recent study looked at anaphylactic reactions and 
inhibitor formation in hemophilia B subjects exposed to recombinant factor IX alone, and 
both recombinant and plasma derived factor IX, and found no difference in the rate of 
inhibitor and anaphylactic reactions between the two groups [17]. However, the sample sizes 
in these groups were small – 7 patients total.
This study has several strengths compared to previous studies of inhibitors in hemophilia B. 
The sample size in this study was the largest population ever studied for hemophilia B and 
inhibitors. In addition, the population in this study was racially and ethnically diverse, which 
reduced the likelihood of a founder effect. To limit the possibility of ascertainment bias, we 
contacted care providers to obtain additional information for potential inhibitor cases 
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identified by screening the UDC data on reported titers and use of bypassing agents and ITI. 
We were able to obtain information for two-thirds of such cases to validate the presence of 
an inhibitor. Most of the patients with reported titers below 1 BU ml−1 did not have an 
inhibitor. Therefore, for the remaining one-third of potential cases for whom we had no 
confirmatory data, we adjusted our algorithm by raising the lower inhibitor titer limit from ≥ 
0.5 to > 1.0 BU ml−1 to decrease the chance of incorrectly classifying patients with these 
lower titer values as having an inhibitor. We believe these efforts improved the validity of 
our findings.
There were several limitations that should be considered when interpreting the results of this 
study. First, as part of the data validation effort we identified a number of apparent 
discrepancies in the presence or absence of an inhibitor as defined by the study on the initial 
query of the UDC database, and that reported in response to our queries of the PI. 
Fortunately, the majority of these discrepancies were the result of our initial assumption that 
reported titers in the UDC database ≥ 0.5 BU ml−1 represented an inhibitor. In fact, values 
reported in the range of 0.5-1.0 BU ml−1 were substantially influenced by variations in the 
limits of detection of low titer inhibitors in different laboratories, and, in some cases due to 
rounding an actual inhibitor titer of < 0.5 BU ml−1 up to 1 rather than down to 0 on the UDC 
data form. Our validation efforts did not extend into the confirmation of the accuracy of 
submitted data on subjects identified on initial query as never having an inhibitor titer ≥ 0.5 
BU ml−1. This was due to the size of the sample in this study, and the difficulty in getting PI 
to respond to our email inquiries. To the extent that subjects who actually had an inhibitor 
but never had an inhibitor titer ≥ 0.5 BU ml−1 in the UDC database during their participation 
in the UDC, our study would underestimate the prevalence of inhibitors in this population.
Another limitation was the use of a database designed for disease surveillance to determine 
prevalence and risk. The lack of information on subjects prior to entry in to the UDC 
hampered efforts to determine the true prevalence of inhibitors, and the potential role of 
previous factor exposure in inhibitor risk. The small number (16) of subjects who developed 
inhibitors after enrollment in the UDC was too small to determine if type of factor used or 
use of prophylaxis prior to inhibitor development was associated with prevalent inhibitors.
We believe this study provides valuable information on a rare complication of a rare disease, 
and serves as a starting point for future studies aimed at determining risk factors for 
inhibitors in hemophilia B patients.
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Identification of Hemophilia B Inhibitor Patients in the UDC Database
Reveals how inhibitor subjects were identified. The initial screen of the database revealed 
203 potential subjects with an inhibitor based on a titer of 0.5 Bu ml−1 or greater. Of these 
128 were shown not to have an inhibitor based on PI response to inquiries of their submitted 
data or UDC data alone for those subjects whose PI did not respond to inquiries. This left 75 
subjects with an inhibitor. ITI= immune tolerance induction therapy; Bypass= use of a 
bypassing agent such as recombinant factor VIIa or an activate prothrombin complex 
concentrate
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 <2 years 89 (2.4) 3 (3.4) <0.001 2 (2.2) 0.055 1 (1.1) < 0.01
 2-5 years 310 (8.2) 12 (3.9) 3 (1.0) 9 (2.9)
 6-10 years 455 (12.0) 18 (4.0) 6 (1.3) 12 (2.6)
 11-20 years 1039 (27.4) 17 (1.6) 7 (0.7) 10 (1.0)
 21-44 years 1173 (31.0) 18 (1.5) 3 (0.3) 15 (1.3)
 45+ years 719 (19.0) 7 (1.0) 3 (0.4) 4 (0.6)
Race/Ethnicity
 White 2821 (74.5) 37 (1.3) < 0.001 15 (0.5) NS 22 (0.8) < 0.001
 Black 391 (10.3) 18 (4.6) 4 (1.0) 14 (3.6)
 Hispanic 357 (9.4) 12 (3.4) 3 (0.8) 9 (2.5)
 Other 207 (5.5) 8 (3.9) 2 (1.0) 6 (2.9)
Severity
 Mild 985 (26.0) 1 (0.1) < 0.001 1 (0.1) < 0.001 0 < 0.001
 Moderate 1418 (37.5) 7 (0.5) 5 (0.4) 2 (0.1)
 Severe 1367 (36.1) 67 (4.9) 18 (1.3) 49 (3.6)
*
Percents do not all total to 100% due to missing data
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Age (vs. 11+ years)
 <11 years 2.5 (1.5 - 4.0) < 0.001
Race/Ethnicity (vs. White)
 Black 2.2 (1.2 - 4.1) < 0.05
 Hispanic 1.4 (0.7 - 2.7) NS
 Other 1.7 (0.8 - 3.8) NS
Severity (vs. Mild/Moderate)
 Severe 13.1 (6.2 – 27.7) < 0.001
CI = Confidence Interval
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Table 3





Age (vs. 11+ years)
 <11 years 2.3 (1.3 - 4.1) 0.004
Race/Ethnicity (vs. White)
 Black 2.8 (1.4 – 5.5) ≤0.05
 Hispanic 1.7 (0.7 - 3.7) NS
 Other 2.1 (0.8 – 5.2) NS
Severity (vs. Mild/Moderate)
 Severe 36.8 (8.9 – 152.8) < 0.001
CI = Confidence Interval
*
24 patients with low titer inhibitors were excluded from this analysis
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